VAXCYTE, INC. Depreciation and Amortization
VAXCYTE, INC. (PCVX) reported Depreciation and Amortization of $5.95 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DepreciationDepletionAndAmortization · last filed 2026-08-05
- VAXCYTE, INC. depreciation, depletion and amortization for the quarter ending 2026-06-30 was $3.00M, a 4.27% increase year-over-year.
- VAXCYTE, INC. depreciation, depletion and amortization for the quarter ending 2026-03-31 was $2.95M, a 0.30% decline year-over-year.
- VAXCYTE, INC. depreciation, depletion and amortization for the quarter ending 2025-12-31 was $7.50M, a 161.77% increase year-over-year.
- VAXCYTE, INC. depreciation, depletion and amortization for the quarter ending 2025-09-30 was $3.06M, a 71.36% increase year-over-year.
- VAXCYTE, INC. depreciation, depletion and amortization for fiscal 2025 was $16.40M, a 134.13% increase from fiscal 2024.
- VAXCYTE, INC. depreciation, depletion and amortization for fiscal 2024 was $7.00M, a 121.89% increase from fiscal 2023.
- VAXCYTE, INC. depreciation, depletion and amortization for fiscal 2023 was $3.16M, a 11.36% increase from fiscal 2022.
- VAXCYTE, INC. depreciation, depletion and amortization for fiscal 2022 was $2.83M, a 57.44% increase from fiscal 2021.
| Period end | Depreciation, Depletion and Amortization 3 month | Depreciation, Depletion and Amortization 6 month | Depreciation, Depletion and Amortization 9 month | Depreciation, Depletion and Amortization 12 month | Depreciation, Depletion and Amortization 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $5.95M 10-Q · filed 2026-08-05 | $13.45M derived: sum of 3 quarters · filed 2026-08-05 | $16.51M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $2.95M 10-Q · filed 2026-05-06 | $10.44M derived: sum of 2 quarters · filed 2026-05-06 | $13.51M derived: sum of 3 quarters · filed 2026-05-06 | $16.39M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $7.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $10.56M derived: sum of 2 quarters · filed 2026-02-24 | $13.44M derived: sum of 3 quarters · filed 2026-08-05 | $16.40M 10-K · filed 2026-02-24 | |
| 2025-09-30 | $3.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $5.94M derived: sum of 2 quarters · filed 2026-08-05 | $8.90M 10-Q · filed 2025-11-04 | $11.76M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $2.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $5.83M 10-Q · filed 2026-08-05 | $8.70M derived: sum of 3 quarters · filed 2026-08-05 | $10.49M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $2.96M 10-Q · filed 2026-05-06 | $5.82M derived: sum of 2 quarters · filed 2026-05-06 | $7.61M derived: sum of 3 quarters · filed 2026-05-06 | $8.96M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | $2.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $4.65M derived: sum of 2 quarters · filed 2026-02-24 | $6.00M derived: sum of 3 quarters · filed 2026-02-24 | $7.00M 10-K · filed 2026-02-24 | |
| 2024-09-30 | $1.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $3.14M derived: sum of 2 quarters · filed 2025-11-04 | $4.14M 10-Q · filed 2025-11-04 | $5.03M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2024-06-30 | $1.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $2.35M 10-Q · filed 2025-08-06 | $3.24M derived: sum of 3 quarters · filed 2026-02-24 | $4.04M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2024-03-31 | $999.00K 10-Q · filed 2025-05-07 | $1.89M derived: sum of 2 quarters · filed 2026-02-24 | $2.69M derived: sum of 3 quarters · filed 2026-02-24 | $3.44M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2023-12-31 | $888.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.69M derived: sum of 2 quarters · filed 2026-02-24 | $2.44M derived: sum of 3 quarters · filed 2026-02-24 | $3.16M 10-K · filed 2026-02-24 | |
| 2023-09-30 | $806.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $1.56M derived: sum of 2 quarters · filed 2024-11-05 | $2.27M 10-Q · filed 2024-11-05 | $3.23M derived: sum of 4 quarters · filed 2025-02-25 | |
| 2023-06-30 | $750.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $1.46M 10-Q · filed 2024-08-06 | $2.42M derived: sum of 3 quarters · filed 2025-02-25 | $3.10M derived: sum of 4 quarters · filed 2025-02-25 | |
| 2023-03-31 | $712.00K 10-Q · filed 2024-05-08 | $1.67M derived: sum of 2 quarters · filed 2025-02-25 | $2.35M derived: sum of 3 quarters · filed 2025-02-25 | $2.96M derived: sum of 4 quarters · filed 2025-02-25 | |
| 2022-12-31 | $959.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $1.64M derived: sum of 2 quarters · filed 2025-02-25 | $2.25M derived: sum of 3 quarters · filed 2025-02-25 | $2.83M 10-K · filed 2025-02-25 | $2.58M 10-K · filed 2023-02-27 |
| 2022-09-30 | $684.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $1.29M derived: sum of 2 quarters · filed 2023-11-06 | $1.88M 10-Q · filed 2023-11-06 | $2.33M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-06-30 | $609.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $1.19M 10-Q · filed 2023-08-08 | $1.65M derived: sum of 3 quarters · filed 2024-02-27 | $2.16M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-03-31 | $582.00K 10-Q · filed 2023-05-08 | $1.04M derived: sum of 2 quarters · filed 2024-02-27 | $1.55M derived: sum of 3 quarters · filed 2024-02-27 | $2.04M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2021-12-31 | $459.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $969.00K derived: sum of 2 quarters · filed 2024-02-27 | $1.45M derived: sum of 3 quarters · filed 2024-02-27 | $1.80M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $510.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $994.00K derived: sum of 2 quarters · filed 2022-11-07 | $1.34M 10-Q · filed 2022-11-07 | $1.67M derived: sum of 4 quarters · filed 2023-02-27 | |
| 2021-06-30 | $484.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $831.00K 10-Q · filed 2022-08-08 | $1.16M derived: sum of 3 quarters · filed 2023-02-27 | $1.50M derived: sum of 4 quarters · filed 2023-02-27 | |
| 2021-03-31 | $347.00K 10-Q · filed 2022-05-09 | $679.00K derived: sum of 2 quarters · filed 2023-02-27 | $1.01M derived: sum of 3 quarters · filed 2023-02-27 | $1.37M derived: sum of 4 quarters · filed 2023-02-27 | |
| 2020-12-31 | $332.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $666.00K derived: sum of 2 quarters · filed 2023-02-27 | $1.02M derived: sum of 3 quarters · filed 2023-02-27 | $1.41M 10-K · filed 2023-02-27 | |
| 2020-09-30 | $334.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $689.00K derived: sum of 2 quarters · filed 2021-11-10 | $1.07M 10-Q · filed 2021-11-10 | $1.41M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2020-06-30 | $355.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $739.00K 10-Q · filed 2021-08-11 | $1.07M derived: sum of 3 quarters · filed 2022-02-28 | $1.38M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2020-03-31 | $384.00K 10-Q · filed 2021-05-11 | $716.00K derived: sum of 2 quarters · filed 2022-02-28 | $1.02M derived: sum of 3 quarters · filed 2022-02-28 | ||
| 2019-12-31 | $332.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $636.00K derived: sum of 2 quarters · filed 2022-02-28 | $1.23M 10-K · filed 2022-02-28 | ||
| 2019-09-30 | $304.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $900.00K 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | $596.00K 10-Q · filed 2020-08-12 | ||||
| 2018-12-31 | $1.04M 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |